keyword
MENU ▼
Read by QxMD icon Read
search

Pramipexole

keyword
https://www.readbyqxmd.com/read/27909317/pramipexole-in-treatment-resistant-depression-possible-role-of-inflammatory-cytokines
#1
Rodrigo Escalona, Jan Fawcett
No abstract text is available yet for this article.
January 2017: Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology
https://www.readbyqxmd.com/read/27889491/pramipexole-enhances-disadvantageous-decision-making-lack-of-relation-to-changes-in-phasic-dopamine-release
#2
Romina Pes, Sean C Godar, Andrew T Fox, Lauren M Burgeno, Hunter J Strathman, David P Jarmolowicz, Paola Devoto, Beth Levant, Paul E M Phillips, Stephen C Fowler, Marco Bortolato
Pramipexole (PPX) is a high-affinity D2-like dopamine receptor agonist, used in the treatment of Parkinson's disease (PD) and restless leg syndrome. Recent evidence indicates that PPX increases the risk of problem gambling and impulse-control disorders in vulnerable patients. Although the molecular bases of these complications remain unclear, several authors have theorized that PPX may increase risk propensity by activating presynaptic dopamine receptors in the mesolimbic system, resulting in the reduction of dopamine release in the nucleus accumbens (NAcc)...
November 23, 2016: Neuropharmacology
https://www.readbyqxmd.com/read/27869754/a-comparative-pharmacokinetics-study-of-the-anti-parkinsonian-drug-pramipexole
#3
Ratih S I Putri, Effi Setiawati, Syifa A Aziswan, Fenny Ong, Raymond R Tjandrawinata, Liana W Susanto
The present study aimed to compare pharmacokinetic parameters of two pramipexole 0.25 mg formulations in order to show bioequivalence. The study was conducted in a randomized, open-label, two-period, two-sequence, and crossover design, involving 23 healthy volunteers. One of the 0.25 mg formulations of pramipexole evaluated in the study was manufactured by PT Dexa Medica, Palembang, Indonesia, the other, used as the reference, by Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Germany. All eligible subjects were required to fast before each drug administration period, which was separated by a one-week washout period...
November 18, 2016: Scientia Pharmaceutica
https://www.readbyqxmd.com/read/27856776/practice-guideline-summary-treatment-of-restless-legs-syndrome-in-adults-report-of-the-guideline-development-dissemination-and-implementation-subcommittee-of-the-american-academy-of-neurology
#4
John W Winkelman, Melissa J Armstrong, Richard P Allen, K Ray Chaudhuri, William Ondo, Claudia Trenkwalder, Phyllis C Zee, Gary S Gronseth, David Gloss, Theresa Zesiewicz
OBJECTIVE: To make evidence-based recommendations regarding restless legs syndrome (RLS) management in adults. METHODS: Articles were classified per the 2004 American Academy of Neurology evidence rating scheme. Recommendations were tied to evidence strength. RESULTS AND RECOMMENDATIONS: In moderate to severe primary RLS, clinicians should consider prescribing medication to reduce RLS symptoms. Strong evidence supports pramipexole, rotigotine, cabergoline, and gabapentin enacarbil use (Level A); moderate evidence supports ropinirole, pregabalin, and IV ferric carboxymaltose use (Level B)...
November 16, 2016: Neurology
https://www.readbyqxmd.com/read/27837576/restless-legs-syndrome-mimicking-s1-radiculopathy
#5
Th Zambelis, B R Wolgamuth, S N Papoutsi, M-I Kontaxaki
Α case of a chronic idiopathic form of a severe type of Restless Legs Syndrome (RLS), which developed during pregnancy and persisted after this, misdiagnosed for 34 years as radiculopathy S1, is reported. In spite of the thorough clinical and laboratory investigation, in addition to constant changes of the therapeutic approach, the diagnosis of S1 radiculopathy could not be confirmed, resulting in a chronic clinical course; the latter was characterized by relapses and remissions not attributed or linked in any way to the treatment (various types of)...
July 2016: Psychiatrikē, Psychiatriki
https://www.readbyqxmd.com/read/27825895/antidepressant-like-effect-of-pramipexole-in-an-inflammatory-model-of-depression
#6
Vicente Lieberknecht, Mauricio Peña Cunha, Stella Célio Junqueira, Igor Dos Santos Coelho, Luiz Felipe de Souza, Adair Roberto Soares Dos Santos, Ana Lúcia S Rodrigues, Rafael Cypriano Dutra, Alcir Luiz Dafre
Pramipexole (PPX), a dopamine D2/3 receptor preferring agonist, is currently in use for the treatment of Parkinson's disease symptoms and restless legs syndrome. Recently, anti-inflammatory properties of PPX have been shown in an autoimmune model of multiple sclerosis, and case reports indicate PPX ameliorates depressive symptoms. Since peripheral inflammation is known to induce depression-like behavior in rodents, we assessed the potential antidepressant effect of PPX in an inflammatory model of depression induced by LPS...
November 5, 2016: Behavioural Brain Research
https://www.readbyqxmd.com/read/27817855/association-of-the-drd2-can-str-and-drd3-ser9gly-polymorphisms-with-parkinson-s-disease-and-response-to-dopamine-agonists
#7
Shaoqing Xu, Jiujiang Liu, Xiaodong Yang, Yiwei Qian, Qin Xiao
Dopamine agonists (DAs) play important roles in the treatment of Parkinson's disease (PD). Currently, it is thought that genetic variations in the genes encoding dopamine receptors (DR) are important factors in determining inter-individual variability in drug responses. To investigate the association between Dopamine receptor D type 2 (DRD2) dinucleotide short tandem repeat (CAn-STR) and Dopamine receptor D type 3 (DRD3) Ser9Gly polymorphisms and the risk of PD, as well as the possible reasons for PD patients using different doses of DAs, we recruited 168 idiopathic PD patients and 182 controls...
August 3, 2016: Journal of the Neurological Sciences
https://www.readbyqxmd.com/read/27810181/a-method-to-switch-from-oral-dopamine-agonists-to-rotigotine-in-patients-with-restless-legs-syndrome-and-mild-augmentation
#8
John W Winkelman, Susan E Mackie, Leslie A Mei, Samuel Platt, Laura Schoerning
BACKGROUND: We examined the short- and long-term efficacy and tolerability of a cross-titration algorithm from oral dopamine agonists to the rotigotine transdermal patch in patients dissatisfied with their restless legs syndrome (RLS) treatment, predominantly with mild augmentation. METHODS: Patients with RLS (n = 20) were recruited at a single site. The cross-titration consisted of decreasing oral dopaminergic agents (ropinirole by 1 mg or pramipexole by 0...
August 2016: Sleep Medicine
https://www.readbyqxmd.com/read/27803657/pramipexole-increases-go-timeouts-but-not-no-go-errors-in-healthy-volunteers
#9
Xue Qing Yang, Daniel Glizer, Andrew Vo, Ken N Seergobin, Penny A MacDonald
Parkinson's disease (PD) is characterized by motor symptoms, such as resting tremor, bradykinesia and rigidity, but also features non-motor complications. PD patients taking dopaminergic therapy, such as levodopa but especially dopamine agonists (DAs), evidence an increase in impulse control disorders (ICDs), suggesting a link between dopaminergic therapy and impulsive pursuit of pleasurable activities. However, impulsivity is a multifaceted construct. Motor impulsivity refers to the inability to overcome automatic responses or cancel pre-potent responses...
2016: Frontiers in Human Neuroscience
https://www.readbyqxmd.com/read/27796464/ergot-and-non-ergot-dopamine-agonists-and-heart-failure-in-patients-with-parkinson-s-disease
#10
François Montastruc, Florence Moulis, Mélanie Araujo, Leila Chebane, Olivier Rascol, Jean-Louis Montastruc
PURPOSE: Some studies have suggested a potential risk of heart failure in patients with Parkinson's disease receiving dopamine (DA) agonists. However, the results are conflicting. We used VigiBase®, the World Health Organization (WHO) Global Individual Case Safety Reports (ICSRs) database, to investigate a potential signal strengthening of heart failure with DA agonists in Parkinsonian patients older than 45 years. METHODS: A case/non-case (disproportionality) analysis was performed in Vigibase® using ICSRs registered between 1978 and May 2016...
October 27, 2016: European Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/27754761/a-novel-pink1-and-park2-dependent-protective-neuroimmune-pathway-in-lethal-sepsis
#11
Rui Kang, Ling Zeng, Yangchun Xie, Zhengwen Yan, Borong Zhou, Lizhi Cao, Daniel J Klionsky, Kevin J Tracey, Jianhua Li, Haichao Wang, Timothy R Billiar, Jianxin Jiang, Daolin Tang
Although the PINK1-PARK2 pathway contributes to the pathogenesis of Parkinson disease, its roles in sepsis (a major challenge for critical care) were previously unknown. Here, we show that pink1(-/-) and park2(-/-) mice are more sensitive to polymicrobial sepsis-induced multiple organ failure and death. The decrease in the circulating level of the neurotransmitter dopamine in pink1(-/-) and park2(-/-) mice accelerates the release of a late sepsis mediator, HMGB1, via HIF1A-dependent anaerobic glycolysis and subsequent NLRP3-dependent inflammasome activation...
October 18, 2016: Autophagy
https://www.readbyqxmd.com/read/27752878/treatment-of-rem-sleep-behavior-disorder
#12
Youngsin Jung, Erik K St Louis
REM sleep behavior disorder (RBD) is a common parasomnia disorder affecting between 1 and 7 % of community-dwelling adults, most frequently older adults. RBD is characterized by nocturnal complex motor behavior and polysomnographic REM sleep without atonia. RBD is strongly associated with synucleinopathy neurodegeneration. The approach to RBD management is currently twofold: symptomatic treatment to prevent injury and prognostic counseling and longitudinal follow-up surveillance for phenoconversion toward overt neurodegenerative disorders...
November 2016: Current Treatment Options in Neurology
https://www.readbyqxmd.com/read/27751669/review-of-safety-and-efficacy-of-sleep-medicines-in-older-adults
#13
REVIEW
Jennifer L Schroeck, James Ford, Erin L Conway, Kari E Kurtzhalts, Megan E Gee, Krista A Vollmer, Kari A Mergenhagen
PURPOSE: Insomnia is problematic for older adults. After behavioral modifications fail to show adequate response, pharmacologic options are used. The pharmacokinetics of agents used to treat insomnia may be altered. This review focuses on the safety and efficacy of medications used to treat insomnia. METHODS: A literature search of Medline, PubMed, and Embase was conducted (January 1966-June 2016). It included systematic reviews, randomized controlled trials, observational studies, and case series that had an emphasis on insomnia in an older population...
November 2016: Clinical Therapeutics
https://www.readbyqxmd.com/read/27749676/tattooing-as-a-symptom-of-impulse-control-disorder-in-a-parkinsonian-patient-with-pramipexole
#14
David Maltête, Floriane Le Goff, Gulden Ozel, Romain Lefaucheur
No abstract text is available yet for this article.
October 4, 2016: Journal of Clinical Psychopharmacology
https://www.readbyqxmd.com/read/27747105/restoring-spinal-noradrenergic-inhibitory-tone-attenuates-pain-hypersensitivity-in-a-rat-model-of-parkinson-s-disease
#15
Lei-Fang Cao, Xiao-Yan Peng, Ya Huang, Bing Wang, Feng-Ming Zhou, Ruo-Xiao Cheng, Li-Hua Chen, Wei-Feng Luo, Tong Liu
In the present study, we investigated whether restoring descending noradrenergic inhibitory tone can attenuate pain in a PD rat model, which was established by stereotaxic infusion of 6-hydroxydopamine (6-OHDA) into the bilateral striatum (CPu). PD rats developed thermal and mechanical hypersensitivity at the 4th week after surgery. HPLC analysis showed that NE content, but not dopamine or 5-HT, significantly decreased in lumbar spinal cord in PD rats. Additional noradrenergic depletion by injection of N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP-4) aggravated pain hypersensitivity in PD rats...
2016: Neural Plasticity
https://www.readbyqxmd.com/read/27725534/transdermal-patch-of-rotigotine-attenuates-freezing-of-gait-in-patients-with-parkinson-s-disease-an-open-label-comparative-study-of-three-non-ergot-dopamine-receptor-agonists
#16
Ken Ikeda, Takehisa Hirayama, Takanori Takazawa, Kiyokazu Kawabe, Yasuo Iwasaki
Objective Parkinson's disease (PD) is characterized by the progressive degeneration of the nigrostriatal dopaminergic neurons. Rotigotine is a non-ergot dopamine receptor agonist (DA). Its transdermal patch maintains the effective concentrations for 24 hours. Freezing of gait (FOG) is a common and devastating symptom in PD patients. Little is known about therapeutic effects of rotigotine on FOG in PD patients. Herein we compared how three non-ergot DAs of rotigotine, pramipexole LA and ropinirole CR influence FOG, besides classical motor deficits in PD patients...
2016: Internal Medicine
https://www.readbyqxmd.com/read/27701719/neuroprotective-effects-of-ellagic-acid-in-a-rat-model-of-parkinson-s-disease
#17
Alireza Sarkaki, Yaghoob Farbood, Mojtaba Dolatshahi, Seyed Mohammad Taqhi Mansouri, Ali Khodadadi
Antioxidants have protective effects against free radicals-induced neural damage in Parkinson's disease (PD). We examined the effects of ellagic acid (EA) on locomotion, pallidal local EEG, and its frequency bands' power and also cerebral antioxidant contents in a rat model of PD induced by 6-hydroxidopamine (6-OHDA). 6-OHDA (16 µg/2µ l) was injected into the right medial forebrain bundle (MFB) in MFB-lesioned rat's brain. Sham group received vehicle instead of 6-OHDA. PD-model was confirmed by rotational test using apomorphine injection...
August 2016: Acta Medica Iranica
https://www.readbyqxmd.com/read/27667864/dextroamphetamine-and-pramipexole-combination-for-treatment-resistant-unipolar-depression
#18
Maju Mathew Koola, Jan Fawcett
No abstract text is available yet for this article.
August 2016: Psychiatric Annals
https://www.readbyqxmd.com/read/27614895/pramipexole-induced-place-preference-after-l-dopa-therapy-and-nigral-dopaminergic-loss-linking-behavior-to-transcriptional-modifications
#19
Simon Loiodice, Poppy Winlow, Sarah Dremier, Etienne Hanon, David Dardou, Omar Ouachikh, Aziz Hafidi, Andre Nogueira da Costa, Franck Durif
RATIONALE: Impulsive-compulsive disorders (ICD) in patients with Parkinson's disease (PD) have been described as behavioral or substance addictions including hypersexuality, gambling, or compulsive medication use of the dopamine replacement therapy (DRT). OBJECTIVES: A remaining challenge is to understand the neuroadaptations leading to reward bias in PD patients under DRT. METHODS: To this end, the appetitive effect of the D2/D3 agonist pramipexole was assessed after chronic exposure to L-dopa in an alpha-synuclein PD rat model...
September 10, 2016: Psychopharmacology
https://www.readbyqxmd.com/read/27594823/pramipexole-impairs-stimulus-response-learning-in-healthy-young-adults
#20
Haley Gallant, Andrew Vo, Ken N Seergobin, Penny A MacDonald
Dopaminergic therapy has paradoxical effects on cognition in Parkinson's disease (PD) patients, with some functions worsened and others improved. The dopamine overdose hypothesis is proposed as an explanation for these opposing effects of medication taking into account the varying levels of dopamine within different brain regions in PD. The detrimental effects of medication on cognition have been attributed to exogenous dopamine overdose in brain regions with spared dopamine levels in PD. It has been demonstrated that learning is most commonly worsened by dopaminergic medication...
2016: Frontiers in Neuroscience
keyword
keyword
32571
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"